Johnson & Johnson (NYSE:JNJ) is one of the biggest pharmaceutical companies in the world. 2024 has been a very important year for the firm as it has agreed to pay a whopping $700 million to settle ...

Johnson & Johnson JNJ and AbbVie ABBV are two major U.S. pharmaceutical companies with robust pipelines and global operations. Both companies have a strong presence in immunology, oncology and ...

Shares with over 50 years of consecutive dividend increases rarely go under the radar. But that might be what’s happening ...

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma ...

JNJ's acquisition of Abiomed increases the prospects of the company advancing innovation in both Medtech and the pharmaceutical business. Sales of JNJ's pharmaceuticals were highest in the nine ...

JNJ) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Domestic manufacturing in the pharmaceutical industry has fallen considerably in the last ...

Johnson & Johnson (JNJ-0.78%) is a healthcare giant that derives the majority of its growth from its pharmaceutical business. J&J boasts a large product lineup that includes immunology drugs ...

The global pharmaceutical industry could generate about ... Argus has a "buy" rating and $185 price target for JNJ stock, which closed at $157.47 on April 17. AbbVie is a global biopharmaceutical ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Short Sellers. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands ...